Clinical trial
A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years
NCT06756269 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 15, 2025
- Completion date
- January 13, 2026
- Enrollment
- 330 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
genital wart, hpv infection, hpv-related carcinoma, hpv-related intraepithelial neoplasia